4893 items matching your search terms.

Shortening of telomere length by metabolic factors in diabetes: protective effects of fenofibrate

Sutanto, S. S. I. McLennan, S. V. Keech, A. C. Twigg, S. M.
JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2019     DOI:10.1007/s12079-019-00521-x

Prevalence of trial registration varies by study characteristics and risk of bias

Tan, A. C. Jiang, I. Askie, L. Hunter, K. Simes, R. J. Seidler, A. L.
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2019     DOI:10.1016/j.jclinepi.2019.05.009

Incidence of adverse events, preventability and mortality in gynaecological hospital admissions: a systematic review and meta-analysis

Tanaka, K. Eriksson, L. Asher, R. Obermair, A.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019     DOI:10.1111/ajo.12937

Evaluation of phase II trial design in advanced pancreatic cancer

Tang, M. Chen, J. Goldstein, D. Links, M. Lord, S. Marschner, I. Simes, R. J. Lee, C. K.
PANCREAS, 2019     DOI:10.1097/MPA.0000000000001429

Challenges of international oncology trial collaboration-a call to action

Tang, M. Joensuu, H. Simes, R. J. Price, T. J. Yip, S. Hague, W. Sjoquist, K. M. Zalcberg, J.
BRITISH JOURNAL OF CANCER, 2019     DOI:10.1038/s41416-019-0532-4

PARAGON: A phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Tang, M. O'Connell, R. L. Amant, F. Beale, P. McNally, O. Sjoquist, K. M. Grant, P. Davis, A. Sykes, P. Mileshkin, L. Moujaber, T. Kennedy, C. J. deFazio, A. Tan, K. Antill, Y. Goh, J. Bonaventura, T. Scurry, J. Friedlander, M.
GYNECOLOGIC ONCOLOGY, 2019     DOI:10.1016/j.ygyno.2019.06.011

Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016)

Tang, M. Schaffer, A. Kiely, B. E. Daniels, B. Simes, R. J. Lee, C. K. Pearson, S. A.
BRITISH JOURNAL OF CANCER, 2019     DOI:10.1038/s41416-019-0612-5

Right or left primary site of colorectal cancer: outcomes from the molecular analysis of the AGITG MAX trial

Tapia Rico, G. Price, T. Tebbutt, N. Hardingham, J. Lee, C. Buizen, L. Wilson, K. Gebski, V. Townsend, A.
CLINICAL COLORECTAL CANCER, 2019     DOI:10.1016/j.clcc.2018.12.002

Current recommendations and practice of oxygen therapy in preterm infants

Tarnow-Mordi, W. Kirby, A.
CLINICS IN PERINATOLOGY, 2019     DOI:10.1016/j.clp.2019.05.015

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis

Toyama, T. Neuen, B. L. Jun, M. Ohkuma, T. Neal, B. Jardine, M. J. Heerspink, H. L. Wong, M. G. Ninomiya, T. Wada, T. Perkovic, V.
DIABETES, OBESITY AND METABOLISM, 2019     DOI:10.1111/dom.13648

Definition of apical descent in women with and without previous hysterectomy: a retrospective analysis

Trutnovsky, G. Robledo, K. P. Shek, K. L. Dietz, H. P.
PLOS ONE, 2019     DOI:10.1371/journal.pone.0213617

Levels of circulating insulin cell-free DNA in women with polycystic ovary syndrome - a longitudinal cohort study

Udesen, P. B. Sorensen, A. E. Joglekar, M. V. Hardikar, A. A. Wissing, M. L. M. Englund, A. M. Dalgaard, L. T.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2019     DOI:10.1186/s12958-019-0478-7

An international analysis of dialysis services reimbursement

van der Tol, A. Lameire, N. Morton, R. L. Van Biesen, W. Vanholder, R.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019     DOI:10.2215/CJN.08150718

Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in advanced gastric cancer

Vasista, A. Stockler, M. Martin, A. Pavlakis, N. Sjoquist, K. Goldstein, D. Gill, S. Jain, V. Liu, G. Kannourakis, G. Kim, Y. H. Nott, L. Snow, S. Burge, M. Harris, D. Jonker, D. Chua, Y. J. Epstein, R. Bonaventura, A. Kiely, B.
ONCOLOGIST, 2019     DOI:10.1634/theoncologist.2018-0613

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Vergote, I. Scambia, G. O'Malley, D. M. Van Calster, B. Park, S. Y. Del Campo, J. M. Meier, W. Bamias, A. Colombo, N. Wenham, R. M. Covens, A. Marth, C. Raza Mirza, M. Kroep, J. R. Ma, H. Pickett, C. A. Monk, B. J. T. RINOVA-3/ENGOT-ov2/GOG- investigators
LANCET ONCOLOGY, 2019     DOI:10.1016/S1470-2045(19)30178-0